** Citi finds improved sales momentum and positive operating cash flow in Bubs Australia's BUB.AX trading update
** Brokerage lifts price target to A$0.14 from A$0.13, maintains "neutral/high risk" rating
** Infant formula maker reported 1H25 EBITDA of A$2.9 mln ($1.82 mln) vs EBITDA loss of A$6.8 mln in the same period last year
** Citi sees co's FY25 rev guidance of A$102 mln to be achievable
** Brokerage, however, flags uncertainty around U.S. FDA approval and sustained positive cash flow as risks
** Stock up 20% so far this year as of last close
($1 = 1.5946 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。